The [[JAK2]]-targeting drug [[fedratinib]] and the BRD4 degrader [[dBET6]] induced [[apoptosis]] and suppressed proliferation in Myeloproliferative Neoplasm stem cells. Together, MPN stem cells display a unique [[phenotype]], including [[cytokine receptor]]s, immune checkpoint molecules, and another clinically relevant target [[antigen]]s. Phenotypic characterization of neoplastic stem cells in MPN and sAML should facilitate their enrichment and the development of better, stem cell-eradicating (curative), therapies
((Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, Greiner G, Slavnitsch K, Hadzijusufovic E, Rülicke T, Dahlhoff M, Hoermann G, Machherndl-Spandl S, Eisenwort G, Fillitz M, Sliwa T, Krauth MT, Bettelheim P, Sperr WR, Koller E, Pfeilstöcker M, Gisslinger H, Keil F, Kralovics R, Valent P. Phenotypic Characterization of Disease-Initiating Stem Cells in JAK2- or CALR-mutated Myeloproliferative Neoplasms. Am J Hematol. 2023 Feb 22. doi: 10.1002/ajh.26889. Epub ahead of print. PMID: 36814396.)).